Covance and the Indiana Clinical and Translational Sciences Institute (CTSI) have entered an agreement to collaborate on the conduct of early clinical trials on behalf of pharma and biopharma companies. The alliance provides the opportunity to bring more Phase I research to Indiana through the clinical research unit located within the IU School of Medicine in Indianapolis, and Covance’s clinical research unit in Evansville.
“The alliance with the Indiana CTSI will help us provide biopharmaceutical clients with quicker access to patients in a hospital setting that supports specialized care and monitoring,” said Rob Aspbury, vice president and general manager, Global Clinical Pharmacology Services at Covance. “With quicker access to patients, we can streamline the drug development process and bring important new medications to patients who need them.”
“The Indiana CTSI works every day to support tremendously talented biomedical scientists whose discoveries have the potential to translate into life-saving new therapies and treatments,” said Anantha Shekhar, M.D., Ph.D., director of the Indiana CTSI, Associate Dean for Translational Research, and the Raymond E. Houk Professor of Psychiatry at the IU School of Medicine. “Our mission is to accelerate the rate at which this research travels out of the lab and into the care of the patients who need it. This alliance with Covance will greatly enhance our ability to accomplish this vital work.”